Purevax RC 10 dose

Target species Cats. Indications for use Active immunisation of cats aged 8 weeks and older. -against feline viral rhinotracheitis to reduce clinical signs, -against calicivirus infection to reduce clinical signs. Onsets of immunity: 1 week after primary vaccination course. Duration of immunity: 1 year after primary vaccination course and 3 years after the last re-vaccination. Contraindications None. Special warnings for each target species Vaccinate healthy animals only. Special precautions for use in animals None. Special precautions to be taken by the person administering the product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions Transient apathy and anorexia as well as hyperthermia (lasting usually for 1 or 2 days) were commonly observed during safety and field studies. A local reaction (slight pain at palpation, itching or limited oedema) that disappears within 1 to 2 weeks at most was commonly observed during safety and field studies. A hypersensitivity reaction has been observed uncommonly in field studies, which may require appropriate symptomatic treatment. The frequency of adverse reactions is defined using the following convention: -very common (more than 1 in 10 animals treated displaying adverse reactions) -common (more than 1 but less than 10 animals treated in 100 animals) -uncommon (more than 1 but less than 10 animals treated in 1,000) -rare (more than 1 but less than 10 animals in 10,000 animals treated) -very rate (less than 1 animal in 10,000 animals treated, including isolated reports). Use during pregnancy, lactation or lay Do not use during the whole pregnancy and lactation. Interactions Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Boehringer Ingelheim non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies. Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Boehringer Ingelheim non-adjuvanted vaccine against rabies. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Vat Rate: 20%